ReviewNature reviews. Immunology2017
Heterogeneity in tuberculosis.
Review in Nature reviews. Immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 300 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
300 citing papers in PubMed, 5 syntheses or guidelines pooled it, 495 citations in OpenAlex.
- Post-pulmonary tuberculosis lung function: a systematic review and meta-analysis.The Lancet. Global health · 2025Pooled it
- Systematic review of innate immune responses againstFrontiers in immunology · 2024Pooled it
- Gene signature discovery and systematic validation across diverse clinical cohorts for TB prognosis and response to treatment.PLoS computational biology · 2023Pooled it
- The immunoregulatory landscape of human tuberculosis granulomas.Nature immunology · 2022Pooled it
- Application of Metagenomic Next-Generation Sequencing inFrontiers in medicine · 2022Pooled it
- Gut-lung axis and microbiome alterations in mycobacterial infections: from pathogenesis to therapeutic potential.Gut microbes · 2026Review
- An adenylyl cyclase switch reroutes carbon from growth to virulence lipids inbioRxiv : the preprint server for biology · 2026Article
- Precision nanomedicine for pulmonary diseases: from molecular targeting to clinical translation.Signal transduction and targeted therapy · 2026Review
- Single-Cell Immune Profiling Suggests Non-Classical Monocyte Is Associated Immunodepression in Tuberculosis Treatment Non-Responders.Journal of cellular and molecular medicine · 2026Article
- Therapeutic remodeling of the tuberculosis granuloma with 1-methyl-D-tryptophan enhances CD8Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Lung Resident T Cells Across the Spectrum of TB Infection and Disease.bioRxiv : the preprint server for biology · 2026Article
- γδ T Cells at the Crossroads of Tuberculosis and COPD: From Early Immunity to Tissue Remodeling.International journal of molecular sciences · 2026Review
- mRNA-based tuberculosis vaccines BNT164a1 and BNT164b1 are immunogenic, well tolerated and efficacious in rodent models.Nature immunology · 2026Article
- Modeling development of tertiary lymphoid structures in pulmonary tuberculosis by 3D profiling and trajectory analysis.bioRxiv : the preprint server for biology · 2026Article
- Infection dose shapes granuloma phenotypes in a humanized mouse model of tuberculosis.Research square · 2026Article
- Sertraline Enhances Bacterial Control without Adversely Affecting the Pharmacodynamic-Pharmacokinetic Properties of Frontline Tuberculosis Drugs.ACS pharmacology & translational science · 2026Article
- The host immune response to Mycobacterium tuberculosis determining protection or disease progression.Nature immunology · 2026Review
- Rv3839-Rv3840 links the endogenous heme biosynthesis pathway with Mycobacterium tuberculosis adaptation to nitric oxide and iron limitation stress.PLoS genetics · 2026Article
- Modified Anti-PstS1 Bi-specific antibodies unlock potent protection against tuberculosis.PLoS pathogens · 2026Article
- The immunometabolic topography of cellular organization and bacterial control in tuberculosis granulomas.Nature immunology · 2026Article
240 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Infection with Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), results in a range of clinical presentations in humans. Most infections manifest as a clinically asymptomatic, contained state that is termed latent TB infection (LTBI); a smaller subset of infected individuals present with symptomatic, active TB. Within these two seemingly binary states, there is a spectrum of host outcomes that have varying symptoms, microbiologies, immune responses and pathologies. Recently, it has become apparent that there is diversity of infection even within a single individual. A good understanding of the heterogeneity that is intrinsic to TB - at both the population level and the individual level - is crucial to inform the development of intervention strategies that account for and target the unique, complex and independent nature of the local host-pathogen interactions that occur in this infection. In this Review, we draw on model systems and human data to discuss multiple facets of TB biology and their relationship to the overall heterogeneity observed in the human disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.